Madrigal Pharmaceuticals
MDGL
226 hedge funds and large institutions have $4.58B invested in Madrigal Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 90 increasing their positions, 59 reducing their positions, and 32 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 6 → 14 (+8)
88% more call options, than puts
Call options by funds: $310M | Put options by funds: $165M
80% more capital invested
Capital invested by funds: $2.54B → $4.58B (+$2.04B)
75% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 32
53% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 59
10% more funds holding
Funds holding: 205 → 226 (+21)
6.31% more ownership
Funds ownership: 94.02% → 100.33% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$106M |
| 2 |
RI
RTW Investments
New York
|
+$88.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$74.3M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$58.4M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$56.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$63.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$46.6M |
| 3 |
O
OrbiMed
New York
|
-$37M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.3M |
| 5 |
Janus Henderson Group
London,
|
-$24.6M |
MDGL Hedge Fund Activity: Q4 2023 in Review
226 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2023, worth a combined $4.58B — up 80% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new MDGL positions and 32 closed out — a net gain of 24 holders — while 90 added to existing stakes and 59 trimmed.
The largest buyer was Paulson & Co, adding an estimated $106M. The largest seller was Marshall Wace, cutting an estimated $63.4M.
- 226 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2023, up from 205 in Q3 2023.
- Funds reported $4.58B of Madrigal Pharmaceuticals stock for Q4 2023, up 80% quarter-over-quarter.
- 56 funds opened new Madrigal Pharmaceuticals positions in Q4 2023 and 32 closed out, a net change of +24 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2023 was Paulson & Co, an estimated $106M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2023 was Marshall Wace, an estimated $63.4M sold.
Based on aggregated 13F filings for Q4 2023.